undamentalytics Newsletter
Sign in

Champions Oncology, Inc. cash flow statement

In fiscal 2026, Champions Oncology, Inc.'s operations generated −$4.5m of cash; it spent $564,000 on capital projects, leaving free cash flow of −$5.0m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Apr 20182019Apr 20192020Apr 20202021Apr 20212022Apr 20222023Apr 20232024Apr 20242025Apr 20252026Apr 2026LTMJul 2026
Cash from operations−1,2261,8622,905−1,6816,4973,972−6,1377,386−4,472−5,564
Depreciation and amortisation3606068259251,5002,1001,9001,6001,4001,312
Stock-based pay1,0046366005989128641,1186541,2371,795
Capital spending1,2298342,2203,2812,3842,872836389564573
Free cash flow−2,4551,028685−4,9624,1131,100−6,9736,997−5,036−6,137
Free cash flow after stock pay−3,45939285−5,5603,201236−8,0916,343−6,273−7,932
Share buybacks————0746340——
Shares issued0—————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CSBR vs PRPOCSBR vs MASSCSBR vs PSNL

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Champions Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Champions Oncology, Inc.